Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB-9778

Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB‐9778
Lina El Badaoui, Stipo Jurcevic, Yotis A. Senis and Alastair J. Barr 2026. Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB‐9778. Pharmacology Research & Perspectives. 14 (4). Advanced online publication. https://doi.org/10.1002/prp2.70301

An investigation of the structure and function of the receptor-type protein tyrosine phosphatase CD148
El Badaoui, Lina 2025. An investigation of the structure and function of the receptor-type protein tyrosine phosphatase CD148. PhD thesis University of Westminster Life Sciences https://doi.org/10.34737/x3w9v

Exercise-Relevant Agonists ADP and AVP Synergistically Enhance Platelet Activation: Modulation by the P2Y₁₂ Inhibitor Cangrelor
Dishkelov, A., Elliott, B. and Jurcevic, S. 2025. Exercise-Relevant Agonists ADP and AVP Synergistically Enhance Platelet Activation: Modulation by the P2Y₁₂ Inhibitor Cangrelor. Jurcevic, S. (ed.) London Lab Live. London 14 - 15 May 2025 London Lab live.

The role of Inflammation in platelet activation (and in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis)
Rashvand, S., Dishkelov, A. and Jurcevic, S. 2024. The role of Inflammation in platelet activation (and in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis). GTH Congress 2024 – 68th Annual Meeting of the Society of Thrombosis and Haemostasis Research – Building Bridges in Coagulation. Vienna, Austria 27 Feb - 01 Mar 2024 Georg Thieme Verlag. https://doi.org/10.1055/s-0044-1779178

Analysis of Receptor-Type Protein Tyrosine Phosphatase Extracellular Regions with Insights from AlphaFold
El Badaoui, L. and Barr, A.J. 2024. Analysis of Receptor-Type Protein Tyrosine Phosphatase Extracellular Regions with Insights from AlphaFold. International Journal of Molecular Sciences. 25 (2) e12507. https://doi.org/10.3390/ijms25020820

Distinguishing Pathological from Physiological Activation of Platelets Potentiated by Exercise
Dishkelov, A., Rashvand, S., Elliott, B. and Jurcevic, S. 2023. Distinguishing Pathological from Physiological Activation of Platelets Potentiated by Exercise. Jurcevic, S. (ed.) European Conference on Thrombosis and Haemostasis. Spain, Valencia 13 - 15 Sep 2023

Preprint: Analysis of Receptor-type Protein Tyrosine Phosphatase Extracellular Regions with Insights from AlphaFold
El Badaoui, L. and Barr, A.J. 2023. Preprint: Analysis of Receptor-type Protein Tyrosine Phosphatase Extracellular Regions with Insights from AlphaFold. Preprints.org. https://doi.org/10.20944/preprints202311.1503.v1

microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells
Mortoglou, M., Miralles, F., Arisan, E.D., Dart, A., Jurcevic, S., Lange, S. and Uysal Onganer, P. 2022. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences. 23 (3) 1275. https://doi.org/10.3390/ijms23031275

Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B
Vögtle, T., Sharma, S., Mori, J., Nagy, Z., Semeniak, D., Scandola, C., Geer, M., Smith, C., Lane, J., Pollack, S., Lassila, R., Jouppila, A., Barr, A.J., Ogg, D., Howard, T., McMiken, H., Warwicker, J., Geh, C., Rowlinson, R., Abbott, W., Eckly, A., Schulze, H., Wright, G., Mazharian, A., Fütterer, K., Rajesh, S., Douglas, M. and Senis, Y. 2019. Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B. eLife. 8 e46840. https://doi.org/10.7554/eLife.46840

JoVE Methods Collection Highlights: Protein-Protein Interactions
Barr, A.J. and Overduin, M. 2019. JoVE Methods Collection Highlights: Protein-Protein Interactions. Journal of Visualized Experiments. 148, p. e59816 e59816. https://doi.org/10.3791/59816

The biochemical basis of disease
Barr, A.J. 2018. The biochemical basis of disease. Essays in Biochemistry. 62 (5), pp. 619-642 https://doi.org/10.1042/EBC20170054. https://doi.org/10.1042/EBC20170054

Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1)
Lee, M.H., Thomas, J.L., Liao, C.L., Jurcevic, S., Crnogorac-Jurcevic, T. and Lin, H.Y. 2018. Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1). Separation and Purification Technology. 192, pp. 213-219. https://doi.org/10.1016/j.seppur.2017.09.071

Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice
Hofmann, I., Geer, M.J., Vögtle, T., Crispin, A., Campagna, D.R., Barr, A.J., Calicchio, M.L., Heising, S., van Geffen, J.P., Kuijpers, M.J.E., Heemskerk, J.W.M., Eble, J.A., Schmitz-Abe, K., Obeng, E.A., Douglas, M., Freson, K., Pondarré, C., Favier, R., Jarvis, G.E., Markianos, K., Turro, E., Ouwehand, W.H., Mazharian, A., Fleming, M.D. and Senis, Y. 2018. Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice. Blood. 132, pp. 1399-1412. https://doi.org/10.1182/blood-2017-08-802769

Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?
Senis, Y. A. and Barr, A.J. 2018. Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out? Molecules. 23 (3) 569. https://doi.org/10.3390/molecules23030569

Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma
Jurcevic, S., Lee, M-H., Thomas, J.L., Liao, C-L., Crnogorac-Jurcevic, T. and Lin, H-Y. 2017. Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma. Microchimica Acta. 184 (6), p. 1773–1780. https://doi.org/10.1007/s00604-017-2169-4

Defining the molecular basis of interaction between R3 receptor-type protein tyrosine phosphatases and VE-cadherin
Dorofejeva, O. and Barr, A.J. 2017. Defining the molecular basis of interaction between R3 receptor-type protein tyrosine phosphatases and VE-cadherin. PLoS ONE. 12 (9) e0184574. https://doi.org/10.1371/journal.pone.0184574

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Simha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology. 57 (2), pp. 194-210. https://doi.org/10.1002/jcph.794

Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans
Jurcevic, S., Juif, P.E., Hamid, C., Greenlaw, R., D'Ambrosio, D. and Dingemanse, J. 2016. Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans. Drug Design, Development and Therapy. 11, pp. 123-131. https://doi.org/10.2147/DDDT.S120399

Automatic Selection of Molecular Descriptors using Random Forest: Application to Drug Discovery
Cano, G., Garcia-Rodriguez, J., Garcia-Garcia, A, Perez-Sanchez, H., Benediktsson, J.A., Thapa, A. and Barr, A.J. 2016. Automatic Selection of Molecular Descriptors using Random Forest: Application to Drug Discovery. Expert Systems with Applications. 72, pp. 151-159. https://doi.org/10.1016/j.eswa.2016.12.008

The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic, S., Humfrey, C., Uddin, M., Warrington, S., Larsson, B. and Keen, C. 2015. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol. . 80 (6), pp. 1324-36. https://doi.org/10.1111/bcp.12724

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski, J.A., Zhou, C., Winters, K.J., Lachno, D.R., Howard, J., Payne, C.D., Mant, T., Jurcevic, S. and Frelinger, A.L. 2015. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 26 (5), pp. 474-479. https://doi.org/10.3109/09537104.2014.940887

Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention
Butterworth, S., Overduin, M. and Barr, A.J. 2014. Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention. Future Medicinal Chemistry. 6 (12), pp. 1423-1437. https://doi.org/10.4155/fmc.14.88

Functional Studies On Receptor-Type Protein Tyrosine Phosphatases Of The R3 Subgroup Using Bimolecular Fluorescence Complementation (BiFC) Assays
Dorofejeva, O., Dwek, M. and Barr, A.J. 2014. Functional Studies On Receptor-Type Protein Tyrosine Phosphatases Of The R3 Subgroup Using Bimolecular Fluorescence Complementation (BiFC) Assays . Pharmacology 2014. London 16 Dec 2014 British Pharmacological Society.

FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells
Rani, A., Greenlaw, R., Runglall, M., Jurcevic, S. and John, S. 2014. FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells. PLoS ONE. 9 (2), p. e90370. https://doi.org/10.1371/journal.pone.0090370

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
Jakubowski, J.A., Zhou, C., Jurcevic, S., Winters, K.J., Lachno, D.R., Frelinger, A.L., Gupta, N., Howard, J., Payne, C.D. and Mant, T. 2014. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thrombosis Research. 133 (2), pp. 190-5. https://doi.org/10.1016/j.thromres.2013.12.008

Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states
Shintre, C.A., Pike, A.C.W., Li, Q., Kim, J.I., Barr, A.J., Goubin, S., Shrestha, L., Yang, J., Berridge, G., Ross, J., Stansfeld, P.J., Sansom, M.S.P., Edwards, A.M., Bountra, C., Marsden, B., von Delft, F., Bullock, A.N., Gileadi, O., Burgess-Brown, N.A. and Carpenter, E.P. 2013. Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. Proceedings of the National Academy of Sciences. 110 (24), pp. 9710-9715. https://doi.org/10.1073/pnas.1217042110

Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice
Alkhamis, T., Barbic, J., Crnogorac-Jurcevic, T., Greenlaw, R.E., Peakman, M. and Jurcevic, S. 2012. Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice. Clinical & Experimental Immunology. 170 (2), p. 139–148 PMC3482360. https://doi.org/10.1111/j.1365-2249.2012.04651.x

The Role of the Fc Region in CD70-specific Antibody Effects on Cardiac Transplant Survival
Jurcevic, S., Shariff, H., Greenlaw, R.E., Meader, L., Gardner, N., Yagita, H., Coccia, M. and Mamode, N. 2011. The Role of the Fc Region in CD70-specific Antibody Effects on Cardiac Transplant Survival. Transplantation. 92 (11), pp. 1194-1201. https://doi.org/10.1097/TP.0b013e3182347ecd

Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class
Salah, E., Ugochukwu, E., Barr, A.J., von Delft, F., Knapp, S. and Elkins, J.M. 2011. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class. Journal of Medicinal Chemistry. 54 (7), pp. 2359-2367. https://doi.org/10.1021/jm101506n

Receptor tyrosine phosphatase PTPγ is a regulator of spinal cord neurogenesis
Hashemia, H., Hurley, M., Gibson, A., Panova, V., Tchetchelnitski, V., Barr, A.J. and Stoker, A.W. 2011. Receptor tyrosine phosphatase PTPγ is a regulator of spinal cord neurogenesis. Molecular and Cellular Neuroscience. 46 (2), pp. 469-482. https://doi.org/10.1016/j.mcn.2010.11.012

CD148 enhances platelet responsiveness to collagen by maintaining a pool of active Src family kinases
Ellison, S., Mori, J., Barr, A.J. and Senis, Y.A. 2010. CD148 enhances platelet responsiveness to collagen by maintaining a pool of active Src family kinases. Journal of Thrombosis and Haemostasis. 8 (7), pp. 1575-1583. https://doi.org/10.1111/j.1538-7836.2010.03865.x

Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development
Barr, A.J. 2010. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Medicinal Chemistry. 2 (10), pp. 1563-1576. https://doi.org/10.4155/fmc.10.241

HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain
Gingras, M.C., Zhang, Y.L., Kharitidi, D., Barr, A.J., Knapp, S., Tremblay, M.L. and Pause, A. 2009. HD-PTP is a catalytically inactive tyrosine phosphatase due to a conserved divergence in its phosphatase domain. PLoS ONE. 4 (4) e5105. https://doi.org/10.1371/journal.pone.0005105

Large scale structural analysis of protein tyrosine phosphatases
Barr, A.J. and Knapp, S. 2009. Large scale structural analysis of protein tyrosine phosphatases. in: Bradshaw, R. and Dennis, E. (ed.) Handbook of cell signaling (2nd edition) San Diego, CA Elsevier. pp. 871-876

Large-scale structural analysis of the classical human protein tyrosine phosphatome
Barr, A.J., Ugochukwu, E., Lee, W.H., King, O.N.F., Filippakopoulos, P., Alfano, I., Savitsky, P., Burgess-Brown, N.A., Muller, S. and Knapp, S. 2009. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell. 136 (2), pp. 352-363. https://doi.org/10.1016/j.cell.2008.11.038

An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients
Jurcevic, S. 2008. An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients. American Journal of Transplantation. 8 (11), pp. 2272-2282. https://doi.org/10.1111/j.1600-6143.2008.02393.x

Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7
Jeeves, M., McClelland, D.M., Barr, A.J. and Overduin, M. 2008. Sequence-specific 1H, 13C and 15N backbone resonance assignments of the 34 kDa catalytic domain of human PTPN7. Biomolecular NMR Assignments. 2 (2), pp. 101-103. https://doi.org/10.1007/s12104-008-9095-7

Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases
Eswaran, J., von Kries, J.P., Marsden, B., Longman, E., Debreczeni, J.E., Ugochukwu, E., Turnbull, A., Lee, W.H., Knapp, S. and Barr, A.J. 2006. Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochemical Journal. 395 (3), pp. 483-491. https://doi.org/10.1042/BJ20051931

Transplant tolerance: models, concepts and facts
Monk, N.J., Hargreaves, R.E.G., Simpson, E., Dyson, J.P. and Jurcevic, S. 2006. Transplant tolerance: models, concepts and facts. Journal of Molecular Medicine. 84 (4), pp. 295-304. https://doi.org/10.1007/s00109-005-0006-4

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
Jurcevic, S., Braselmann, S., Taylor, V., Zhao, H., Wang, S. and Masuda, E.S. 2006. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Journal of Pharmacology and Experimental Therapeutics. 319 (3), pp. 998-1008 109058/3152109. https://doi.org/10.1124/jpet.106.109058

The crystal structure of human receptor protein tyrosine phosphatase κ phosphatase domain 1
Eswaran, J., Debreczeni, J.E., Longman, E., Barr, A.J. and Knapp, S. 2006. The crystal structure of human receptor protein tyrosine phosphatase κ phosphatase domain 1. Protein Science. 15 (6), pp. 1500-1505. https://doi.org/10.1110/ps.062128706

Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution
Barr, A.J., Debreczeni, J.E., Eswaran, J. and Knapp, S. 2006. Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution. Proteins. 63 (4), pp. 1132-1136. https://doi.org/10.1002/prot.20958

MAPK-specific tyrosine phosphatases: new targets for drug discovery?
Barr, A.J. and Knapp, S. 2006. MAPK-specific tyrosine phosphatases: new targets for drug discovery? Trends in Pharmacological Sciences. 27 (10), pp. 525-530. https://doi.org/10.1016/j.tips.2006.08.005

Selective depletion of activated T cells: the CD40L-specific antibody experience
Hargreaves, R.E.G., Monk, N.J. and Jurcevic, S. 2004. Selective depletion of activated T cells: the CD40L-specific antibody experience. TRENDS in Molecular Medicine. 10 (3), pp. 130-135. https://doi.org/10.1016/j.molmed.2004.01.009

Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade
Monk, N.J., Hargreaves, R.E.G., Marsh, J.E., Farrar, C.A., Sacks, S.H., Millrain, M., Simpson, E., Dyson, J. and Jurcevic, S. 2003. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nature Medicine. 9 (10), pp. 1275-1280. https://doi.org/10.1038/nm931

Phospholipase C-β 2 interacts with mitogen-activated protein kinase kinase 3
Barr, A.J., Marjoram, R.J., Xu, J. and Snyderman, R. 2002. Phospholipase C-β 2 interacts with mitogen-activated protein kinase kinase 3. Biochemical and Biophysical Research Communications. 293 (1), pp. 647-652. https://doi.org/10.1016/S0006-291X(02)00259-0

RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses
Richardson, R.M., Marjoram, R.J., Barr, A.J. and Snyderman, R. 2001. RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. Biochemistry. 40 (12), pp. 3583-3588. https://doi.org/10.1021/bi0019242

Insect Cell systems to Study the Communication of Mammalian Receptors and G proteins
Windh, R., Barr, A.J. and Manning, D.R. 2000. Insect Cell systems to Study the Communication of Mammalian Receptors and G proteins. in: Kenakin, T. and Angus, J.A. (ed.) The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems Berlin Heidelberg Springer. pp. 335-362

Function and regulation of chemoattractant receptors
Haribabu, B., Richardson, R.M., Verghese, M.W., Barr, A.J., Zhelev, D.V. and Snyderman, R. 2000. Function and regulation of chemoattractant receptors. Immunologic Research. 22 (2-3), pp. 271-279. https://doi.org/10.1385/IR:22:2-3:271

Identification of a region at the N-terminus of phospholipase C-beta 3 that interacts with G protein beta gamma subunits
Barr, A.J., Ali, H., Haribabu, B., Snyderman, R. and Smrcka, A.V. 2000. Identification of a region at the N-terminus of phospholipase C-beta 3 that interacts with G protein beta gamma subunits. Biochemistry. 39 (7), pp. 1800-1806. https://doi.org/10.1021/bi992021f

Agonist-promoted GTP[S35]-binding as a probe for receptor.G protein communication in Sf9 cells
Barr, A.J. and Manning, D.R. 1999. Agonist-promoted GTP[S35]-binding as a probe for receptor.G protein communication in Sf9 cells. in: Manning, D.R. (ed.) G proteins: techniques of analysis Boca Raton, FL CRC Press. pp. 227-246

Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 families of heterotrimeric G proteins
Windh, R., Lee, M.J., Hla, T., An, S., Barr, A.J. and Manning, D.R. 1999. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the Gi, Gq, and G12 families of heterotrimeric G proteins. Journal of Biological Chemistry. 274 (39), pp. 27351-27358. https://doi.org/10.1074/jbc.274.39.27351

Differential regulation of formyl peptide and platelet-activating factor receptors: role of phospholipase Cbeta3 phosphorylation by protein kinase A
Ali, H., Sozzani, S., Fisher, I., Barr, A.J., Richardson, R.M., Haribabu, B. and Snyderman, R. 1998. Differential regulation of formyl peptide and platelet-activating factor receptors: role of phospholipase Cbeta3 phosphorylation by protein kinase A. Journal of Biological Chemistry. 273 (18), pp. 11012-11016. https://doi.org/10.1074/jbc.273.18.11012

Reconstitution of receptors and GTP-binding regulatory proteins (G Proteins) in Sf9 Cells: a direct evaluation of selectivity in receptor.G protein coupling
Barr, A.J., Brass, L.F. and Manning, D.R. 1997. Reconstitution of receptors and GTP-binding regulatory proteins (G Proteins) in Sf9 Cells: a direct evaluation of selectivity in receptor.G protein coupling. Journal of Biological Chemistry. 272 (4), pp. 2223-2229. https://doi.org/10.1074/jbc.272.4.2223

Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in spodoptera frugiperda cells: distinguishing inverse agonists from neutral antagonists
Barr, A.J. and Manning, D.R. 1997. Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in spodoptera frugiperda cells: distinguishing inverse agonists from neutral antagonists. Journal of Biological Chemistry. 272 (52), pp. 32979-32987. https://doi.org/10.1074/jbc.272.52.32979

Protein kinase C mediates delayed inhibitory feedback regulation of human neurokinin type 1 receptor activation of phospholipase C in UC11 astrocytoma cells
Barr, A.J. and Watson, S.P. 1994. Protein kinase C mediates delayed inhibitory feedback regulation of human neurokinin type 1 receptor activation of phospholipase C in UC11 astrocytoma cells. Molecular Pharmacology. 46 (2), pp. 266-273.

Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors
Barr, A.J. and Watson, S.P. 1993. Non-peptide antagonists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK1 receptors. British Journal of Pharmacology. 108 (1), pp. 223-227. https://doi.org/10.1111/j.1476-5381.1993.tb13466.x

The presence of NK3 tachykinin receptors on rat uterus
Barr, A.J., Watson, S.P., Bernal, A.L. and Nimmo, A.J. 1991. The presence of NK3 tachykinin receptors on rat uterus. European Journal of Pharmacology. 203 (2), pp. 287-290. https://doi.org/10.1016/0014-2999(91)90726-7